Cardiometabolic Risk Reversal: What Three Studies Actually Show

The Setup

Someone assembled three separate studies under the banner of "cardiometabolic risk reversal" and hoped the label would do the heavy lifting. It doesn't. What follows is a breakdown of what each study actually measured, why bundling them under that label is intellectually dishonest, and what real evidence for this kind of claim would look like.

The Three Studies — What They Actually Are

Study 1: Anti-Inflammatory Diet and Colorectal Cancer Biomarkers

This retrospective study examined dietary adherence scores against gut microbiome composition and colorectal cancer-associated biomarkers. The operative word is retrospective — researchers looked backward at dietary records and health data that already existed. This design is a confounder factory.

People who eat anti-inflammatory diets don't just eat differently. They tend to exercise more, sleep better, smoke less, earn more, and diverge from less health-conscious populations across dozens of lifestyle dimensions simultaneously. Disentangling diet from that bundle is essentially impossible in a retrospective design with no randomization.

There is also a reverse causality problem that the study doesn't resolve: gut dysbiosis can alter food preferences and appetite. You cannot rule out that the microbiome shaped the diet rather than the other way around. This study tells you these things travel together. It does not tell you that changing your diet will fix your microbiome.

Study 2: Alpha-Aminoadipic Acid (2-AAA) and Lysine Ingestion

This is actually the most intellectually honest paper of the three. The study is a mechanistic probe: healthy volunteers consumed lysine, plasma 2-AAA levels were measured before and after, and the researchers noted that elevated 2-AAA has been associated with diabetes risk in separate epidemiological research.

The problem is what this finding is being asked to carry. Short-term postprandial spikes in a metabolite in healthy volunteers tell us almost nothing about long-term disease risk. Your insulin spikes after you eat a banana. That doesn't mean bananas cause diabetes. The study explicitly states there are no clinical recommendations to draw from it. Whoever bundled this into a "risk reversal" package ignored that caveat entirely.

Study 3: LAP Index and NAFLD Severity

This cross-sectional study measured the Lipid Accumulation Product (LAP) index — a composite of waist circumference and fasting triglycerides — against severity of non-alcoholic fatty liver disease in obese outpatient clinic patients. Cross-sectional means everyone was measured once, at a single point in time. No follow-up, no intervention, no longitudinal tracking.

The finding: higher LAP correlates with worse liver function markers. This is not surprising. Waist circumference and triglycerides are both markers of metabolic dysfunction, and NAFLD is a metabolic disease. Confirming that patients with more metabolic dysfunction have worse metabolic disease is not a revelation — it's a circular observation dressed in an index.

More critically, this was a highly selected population (obese patients already in specialized outpatient care) that does not generalize to the public. And because it's cross-sectional, there is zero evidence that lowering someone's LAP score changes their liver outcomes.

The Design Problem — What "Observational" Actually Means

All three studies share the same fundamental limitation: they observe. None of them intervene. This matters enormously when the framing is "risk reversal" — a term that implies you can do something and get a result.

Observational studies can establish association. They cannot establish causation without extremely careful confounding control, which is almost never fully achievable with lifestyle and dietary data. The checklist for evaluating any observational claim:

• In which direction does the association run?
• In which population was it observed, and does that population generalize to yours?
• How many confounders were adjusted for, and how rigorously?
• Is there a plausible biological mechanism, and was it actually tested?

These three papers score poorly on most of those criteria when the question being asked is "can I reverse cardiometabolic risk by following these findings?"

The Editorial Trick

The deeper problem isn't the studies themselves — it's what's done with them. This is a rhetorical move common in wellness media: take three mechanistic or associative findings, apply an aspirational label, and let readers connect dots that the data doesn't connect.

Diet correlates with microbiome composition. A metabolite responds acutely to an amino acid. An index correlates with disease severity. Assembling these under "cardiometabolic risk reversal" implies a coherent chain — that you can manipulate 2-AAA with lysine, improve your microbiome with anti-inflammatory eating, and track your progress with the LAP index — that none of these studies actually supports. You can't build a reversal protocol out of three snapshot associations in three different populations.

Three observations in search of a narrative isn't a clinical strategy. It's content.

What Convincing Evidence Would Look Like

To actually claim cardiometabolic risk reversal, you'd need:

• A randomized controlled trial where participants are assigned to specific interventions — not self-selected dietary patterns
• Follow-up of at least 12–24 months
• Clinical endpoints: cardiovascular events, diabetes incidence, or liver fibrosis progression — not surrogate biomarkers
• Longitudinal gut microbiome sequencing at multiple timepoints to establish mechanistic plausibility
• A representative population, not a specialized clinic cohort

One well-designed RCT would outweigh all three of these papers combined.

Verdict

Three observational studies with the expected limitations of observational designs do not constitute a risk reversal strategy. The findings are interesting in the way preliminary findings are interesting — they generate hypotheses, point at mechanisms, suggest questions worth studying. But "interesting hypothesis" and "actionable strategy" are different categories, and the gap between them is exactly what rigorous trials exist to close.

The packaging is the problem, not the science. Individually, these papers are fine. Together, relabeled as evidence for something none of them demonstrates, they're doing rhetorical work the data wasn't designed to do. This isn't a reversal protocol. It's three observations dressed up in a trench coat and hoping to get into the club.